Chronic rhinosinusitis is one of the most common chronic inflammatory conditions of the airways, affecting a substantial share of adults worldwide and imposing significant quality-of-life and economic burdens. It is defined by persistent inflammation of the mucosa lining the nose and paranasal sinuses, and it is classified into clinical phenotypes such as disease with or without nasal polyps under the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 criteria. Despite its prevalence, the immunological mechanisms driving the disease remain incompletely understood, and one intriguing line of investigation has focused on the unexpected role of taste receptors in airway defense.

The science behind that line of research is genuinely striking. In 2009, a landmark study showed that the motile cilia of human airway epithelial cells are chemosensory, meaning they can detect chemicals in their environment. T2R38, the receptor encoded by TAS2R38, recognizes acyl-homoserine lactones, which are quorum-sensing molecules that bacteria use to communicate and coordinate the formation of biofilms. When T2R38 binds these bacterial signals, it triggers a cascade that produces nitric oxide within the epithelial cells. Nitric oxide, in turn, stimulates the cilia to beat faster and directly harms bacteria, accelerating mucociliary clearance, the conveyor-belt mechanism that sweeps mucus and trapped microbes out of the airways. In other words, the same receptor that lets people perceive the bitterness of compounds such as those in cruciferous vegetables also functions as a microbial sentry in the nose.

This dual role has clinical consequences. Previous work has linked T2R38 receptor polymorphisms to susceptibility to upper respiratory infections and to chronic rhinosinusitis requiring surgery, and genotype has even been reported to predict surgical outcomes in certain disease subtypes. Other studies have examined T2R38 expression and function in diseased sinus tissue and nasal polyps. But a methodological question has hovered over this entire literature: if researchers biopsy one anatomical site, say the inferior turbinate, can they generalize the measured TAS2R38 expression to the rest of the sinonasal cavity? If expression varied substantially between the maxillary, ethmoid, frontal, and sphenoid sinuses, or between polypoid and non-polypoid tissue, then sampling location could silently bias results and make studies from different centers difficult to compare.

To settle the question, the Vietnamese team designed a prospective cross-sectional study embedded in routine endoscopic sinus surgery. They recruited 67 patients with chronic rhinosinusitis diagnosed according to the EPOS 2020 criteria and harvested mucosal specimens from up to six anatomical sites in each patient: the inferior turbinate, the maxillary sinus, the ethmoid sinus, the frontal sinus, the sphenoid sinus, and nasal polyps when present. They also collected 29 non-inflammatory septal specimens as controls. In total, 337 mucosal samples were collected, an unusually dense spatial sampling of a single patient population for this kind of molecular study.

The molecular measurements followed rigorous standards. Relative TAS2R38 messenger RNA expression was quantified by reverse transcription quantitative polymerase chain reaction, or RT-qPCR, performed in accordance with the MIQE guidelines, the internationally accepted quality framework for quantitative PCR experiments, and normalized to the housekeeping gene GAPDH. After strict quality control, which excluded 84 specimens because of cycle threshold values outside acceptable limits or minute fibrous tissue yields, 253 valid specimens from 55 patients remained for analysis. The final dataset included 52 inferior turbinate samples, 50 maxillary samples, 49 ethmoid samples, 44 polyp samples, 43 frontal samples, and 15 sphenoid samples.

The analytical approach was as important as the sampling design. Because multiple biopsies came from the same patient, the data points are statistically clustered, and treating them as independent would inflate false confidence. The researchers therefore used linear mixed-effects modeling with patient-specific random intercepts as their principal framework, a technique that explicitly separates variation between individuals from variation within individuals across anatomical sites. They supplemented this with sensitivity analyses and fold-difference calculations based on the standard 2 to the power of negative delta delta Cq method.

The results were unambiguous. Mean delta Cq values, a measure inversely related to gene expression, were remarkably comparable across subsites, ranging only from 2.06 to 2.81, and an exploratory analysis of variance found no significant differences among sites. In the principal mixed-effects model, anatomical sampling site showed no statistically significant association with TAS2R38 expression. Crucially, the variance decomposition told the deeper story: inter-individual biological variance substantially exceeded intra-individual spatial variation, with an intraclass correlation coefficient of 0.333, meaning roughly a third of the variance in expression was attributable to differences between patients rather than differences between locations within a patient. The robustness of the conclusion held across six sensitivity scenarios, including the exclusion of the small sphenoid subset and multivariable adjustments for age and sex.

One exploratory observation adds biological intrigue. Diseased mucosa demonstrated an approximately 2.48-fold upregulation of TAS2R38 relative to non-site-matched septal controls, hinting that the inflammatory environment of chronic rhinosinusitis may itself alter the expression of this chemosensory defense receptor. The authors characterize this comparison as exploratory, and the control tissue was not matched to the disease sites, so it should be interpreted with appropriate caution. Still, it aligns with a growing body of work suggesting that the bitter taste receptor system is dynamically involved in airway inflammation rather than being a static genetic fixture.

The practical implications reach well beyond the operating theater. For translational airway researchers, the study provides evidence that inferior turbinate biopsy, one of the simplest and most accessible sampling procedures in the nose, could serve as a pragmatic surrogate for investigating sinonasal chemosensory innate defense, sparing patients and researchers the complexity of multi-site sampling. For clinicians, the finding reinforces the idea that a patient’s individual biology, including their TAS2R38 genotype and expression profile, may matter more for disease susceptibility and treatment response than the specific anatomy involved. And for the broader field of innate immunity, it adds a methodological anchor to a rapidly evolving story about how the airways borrow the molecular machinery of taste to defend themselves against microbial invaders. As research into bitter receptor-based therapies for airway disease continues to gather momentum, knowing that one well-chosen biopsy can speak for the whole cavity removes a persistent source of uncertainty from the evidence base.

Subject of Research: TAS2R38 bitter taste receptor gene expression across sinonasal anatomical sites in chronic rhinosinusitis

Article Title: Anatomical sampling site is not associated with TAS2R38 gene expression in chronic rhinosinusitis: A cross-sectional RT-qPCR study

Article References: Cao, M. T., Luong, T. L. A., & Nguyen, X. N. (2026). Anatomical sampling site is not associated with TAS2R38 gene expression in chronic rhinosinusitis: A cross-sectional RT-qPCR study. Molecular Biology Reports, 53(1), Article 1659. https://doi.org/10.1007/s11033-026-12838-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12838-z

Keywords: TAS2R38, bitter taste receptor, chronic rhinosinusitis, nasal polyps, RT-qPCR, linear mixed-effects model, innate immunity, nitric oxide, mucociliary clearance, endoscopic sinus surgery, inferior turbinate, sinonasal mucosa